Sustained Benefit of 6-Month Topiramate Treatment for Migraine

J Gordon Millichap

doi:10.15844/pedneurbriefs-21-12-4

Sustained Benefit of 6-Month Topiramate Treatment for Migraine

Pediatric Neurology Briefs

Volume 21 (2007): Issue 12

By: J Gordon Millichap

Open Access

|Dec 2007

Abstract

The effects of discontinuing topiramate after a treatment period of 6 months in 818 patients with migraine, enrolled from 88 clinics in 21 countries in Europe, the UK and Turkey, are reported from University Duisburg-Essen, Germany.

References

Diener HC Agosti R Allais G Bergmans P Bussone G Davies B Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomized, double-blind, placebo-controlled trial Lancet Neurol 2007 Dec 6 12 1054 1062 10.1016/S1474-4422(07)70272-7 17988947
Open DOI Search in Google Scholar Back to article
Couch JR Jr Preventive antimigraine therapy: the long-term outlook Lancet Neurol 2007 Dec 6 12 1035 1036 10.1016/S1474-4422(07)70273-9 17988948
Open DOI Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.15844/pedneurbriefs-21-12-4 | Journal eISSN: 2166-6482

Journal RSS Feed

Language: English

Page range: 91 - 92

Published on: Dec 1, 2007

Published by: Pediatric Neurology Briefs Publishers

In partnership with: Paradigm Publishing Services

Keywords:

Topiramate,

Migraine Prophylactic Treatment,

Rebound Headache

© 2007 J Gordon Millichap, published by Pediatric Neurology Briefs Publishers
This work is licensed under the Creative Commons Attribution 4.0 License.

Volume 21 (2007): Issue 12